Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ghulam J Mufti

Showing results (131-140 of 224) with videos related to

Pageof 23
Sort By:
Haematologica|February 21, 2009
Cord blood stem cells for hematopoietic stem cell transplantation in the UK: how big should the bank be?Sergio Querol, Ghulam J Mufti, Steven G E Marsh, et al.
Leukemia & Lymphoma|February 7, 2009
Anti-tumor immunity in a model of acute myeloid leukemiaAdam T C Cheuk, James W Wells, Lucas Chan, et al.
Archives of Dermatology|September 19, 2007
Eczematoid graft-vs-host disease: a novel form of chronic cutaneous graft-vs-host disease and its response to psoralen UV-A therapyDaniel Creamer, Claire L Martyn-Simmons, Genevieve Osborne, et al.
Haematologica|January 10, 2013
Spliceosome mutations exhibit specific associations with epigenetic modifiers and proto-oncogenes mutated in myelodysplastic syndromeSyed A Mian, Alexander E Smith, Austin G Kulasekararaj, et al.
British Journal of Haematology|September 3, 2014
A comprehensive diagnostic approach using galactomannan, targeted β-d-glucan, baseline computerized tomography and biopsy yields a significant burden of invasive fungal disease in at risk haematology patientsM Mansour Ceesay, Sujal R Desai, Lisa Berry, et al.
Leukemia Research|December 24, 2013
Challenges of phase III trial design for novel treatments in diseases with no standard treatment: the AZA-001 myelodysplasia study modelPierre Fenaux, John F Seymour, Valeria Santini, et al.
British Journal of Haematology|January 29, 2014
Bone marrow hypocellularity does not affect tolerance or efficacy of azacitidine in patients with higher-risk myelodysplastic syndromesJohn F Seymour, John M Bennett, Alan F List, et al.
British Journal of Haematology|October 3, 2002
Allogeneic stem cell transplantation in the myelodysplastic syndromes: interim results of outcome following reduced-intensity conditioning compared with standard preparative regimensJane E Parker, Tariq Shafi, Antonio Pagliuca, et al.
Critical Reviews in Oncology/Hematology|May 11, 2010
Effects of azacitidine compared with conventional care regimens in elderly (≥ 75 years) patients with higher-risk myelodysplastic syndromesJohn F Seymour, Pierre Fenaux, Lewis R Silverman, et al.
The Journal of Investigative Dermatology|February 18, 2011
Erythropoietic uroporphyria associated with myeloid malignancy is likely distinct from autosomal recessive congenital erythropoietic porphyriaRobert P E Sarkany, Sally H Ibbotson, Sharon D Whatley, et al.
Pageof 23

Showing results (131-140 of 224) with videos related to

Sort By:
Pageof 23
Haematologica|February 21, 2009
Cord blood stem cells for hematopoietic stem cell transplantation in the UK: how big should the bank be?Sergio Querol, Ghulam J Mufti, Steven G E Marsh, et al.
Leukemia & Lymphoma|February 7, 2009
Anti-tumor immunity in a model of acute myeloid leukemiaAdam T C Cheuk, James W Wells, Lucas Chan, et al.
Archives of Dermatology|September 19, 2007
Eczematoid graft-vs-host disease: a novel form of chronic cutaneous graft-vs-host disease and its response to psoralen UV-A therapyDaniel Creamer, Claire L Martyn-Simmons, Genevieve Osborne, et al.
Haematologica|January 10, 2013
Spliceosome mutations exhibit specific associations with epigenetic modifiers and proto-oncogenes mutated in myelodysplastic syndromeSyed A Mian, Alexander E Smith, Austin G Kulasekararaj, et al.
British Journal of Haematology|September 3, 2014
A comprehensive diagnostic approach using galactomannan, targeted β-d-glucan, baseline computerized tomography and biopsy yields a significant burden of invasive fungal disease in at risk haematology patientsM Mansour Ceesay, Sujal R Desai, Lisa Berry, et al.
Leukemia Research|December 24, 2013
Challenges of phase III trial design for novel treatments in diseases with no standard treatment: the AZA-001 myelodysplasia study modelPierre Fenaux, John F Seymour, Valeria Santini, et al.
British Journal of Haematology|January 29, 2014
Bone marrow hypocellularity does not affect tolerance or efficacy of azacitidine in patients with higher-risk myelodysplastic syndromesJohn F Seymour, John M Bennett, Alan F List, et al.
British Journal of Haematology|October 3, 2002
Allogeneic stem cell transplantation in the myelodysplastic syndromes: interim results of outcome following reduced-intensity conditioning compared with standard preparative regimensJane E Parker, Tariq Shafi, Antonio Pagliuca, et al.
Critical Reviews in Oncology/Hematology|May 11, 2010
Effects of azacitidine compared with conventional care regimens in elderly (≥ 75 years) patients with higher-risk myelodysplastic syndromesJohn F Seymour, Pierre Fenaux, Lewis R Silverman, et al.
The Journal of Investigative Dermatology|February 18, 2011
Erythropoietic uroporphyria associated with myeloid malignancy is likely distinct from autosomal recessive congenital erythropoietic porphyriaRobert P E Sarkany, Sally H Ibbotson, Sharon D Whatley, et al.
Pageof 23